Patents Examined by Stacy B. Chen
  • Patent number: 11667671
    Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising at least 15 mg/ml multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, wherein the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml; b) contacting a liquid sample comprising an immunoglobulin with the separation matrix; c) washing the separation matrix with a washing liquid; d) eluting the immunoglobulin from the separation matrix with an elution liquid; and e) cleaning the separation matrix with a cleaning liquid comprising at least 0.5 M NaOH.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: June 6, 2023
    Assignee: Cytiva BioProcess R&D AB
    Inventors: Annika Forss, Mats Ander, Tomas Bjorkman, Hans Blom, Jesper Hansson, Gustav Rodrigo
  • Patent number: 11667931
    Abstract: The present invention relates to the production of adeno-associated viral vectors in insect cells. The insect cells therefore comprise a first nucleotide sequence encoding the adeno-associated virus (AAV) capsid proteins, whereby the initiation codon for translation of the AAV VP1 capsid protein is an AUG. Upstream of the VP1 open reading frame an alternative out of frame start codon is placed such that translation initiation of the VP1 protein is modified, i.e. reduced, to allow production of VP1:VP2:VP3 in a good stoichiometry resulting in AAV with high potency.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: June 6, 2023
    Assignee: uniQure IP B.V.
    Inventors: David Johannes Francois Du Plessis, Olivier Ter Brake, Sebastiaan Menno Bosma, Harald Peter Albert Petry, Jacek Lubelski
  • Patent number: 11649467
    Abstract: The invention provides adenoviral vectors comprising transgenes encoding Chikungunya virus antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Chikungunya virus infections.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: May 16, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Benjamin Wizel, Martine Harvey, Lucile Warter, Kate Luisi
  • Patent number: 11633468
    Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: April 25, 2023
    Assignee: Vactech Oy
    Inventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
  • Patent number: 11623941
    Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, b) contacting a liquid sample comprising an immunoglobulin with the separation matrix, c) washing said separation matrix with a washing liquid, d) eluting the immunoglobulin from the separation matrix with an elution liquid, and e) cleaning the separation matrix with a cleaning liquid, wherein the alkali-stabilized Protein A domains comprise mutants of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 51 or SEQ ID NO: 52, wherein the amino acid residues at positions 13 and 44 of SEQ ID NO: 51 or 52 are asparagines and wherein at least the asparagine residue at position 3 of SEQ ID NO: 51 or 52 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leuc
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: April 11, 2023
    Assignee: CYTIVA BIOPROCESS R&D AB
    Inventors: Annika Kristina Forss, Gustav Jose Rodrigo, Tomas Bjorkman, Jesper Ulf Hansson, Mats Ander
  • Patent number: 11612337
    Abstract: The present invention includes a system and device for aiding in the diagnosis of a physiological abnormality resulting in detectable, measurable variations in contents of breathed air. The system includes a handheld unit defining an airway, wherein the airway includes a plurality of sensors adapted to measure a plurality of parameters related to the presence of a physiological abnormality. The system further includes a control unit remotely connected to the handheld unit. The control unit includes a controller adapted to receive input signals from the handheld unit and remit output signals in response thereto. The output signals are usable by a user in determining the presence or absence of a physiological abnormality. The control unit further also can include a display adapted to display the output signals to a user thereby easing the determination of the physiological abnormality. The system further includes a mouthpiece selectively connectable to the handheld unit.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: March 28, 2023
    Assignee: DEKA Products Limited Partnership
    Inventors: Derek G. Kane, Gregory R. Lanier, Jr., Eric Soderberg, Benjamin W. Jones, Jr., Paul Marquis
  • Patent number: 11596686
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: August 9, 2022
    Date of Patent: March 7, 2023
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • Patent number: 11591364
    Abstract: Saponin extracts containing at least 93% QS-21 main peak and 0.25-3% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: February 28, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Ahmad Taimour Baig, Felicie Georgette Colette Denet, Juan Jose Diaz Garcia, Chad Austin Farrenburg, Lora Lea Lawrence, Kent Raymond Myers, Jeri Kay Sandvick, Jeb Yeatts Vandenburg
  • Patent number: 11576966
    Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: February 14, 2023
    Assignee: CureVac SE
    Inventors: Susanne Rauch, Hans Wolfgang Große, Benjamin Petsch
  • Patent number: 11572390
    Abstract: Chimeric proteins that comprise one or more amino acid sequences of an insect-specific flavivirus and one or more other immunogenic proteins are provided. The chimeric proteins are suitably capable of forming virus particles. The chimeric protein and/or virus particle may be suitable for delivery to a subject to elicit an immune response to a pathogen and/or for diagnosis or detection of a pathogen. Also provided are nucleic acids and vectors encoding the chimeric proteins, and isolated chimeric insect-specific flaviviruses comprising the chimeric proteins and/or nucleic acids.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: February 7, 2023
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Roy Hall, Jody Hobson-Peters, Alexander Khromykh, Daniel Watterson, Mn Setoh, Thisun Piyasena, Agathe Colmant, Jessica Harrison, N Ata Lee Newton, Laura Vet, Helle Bielefeldt-Ohmann
  • Patent number: 11564985
    Abstract: A fusion protein is provided which is based on a self-assembling gene-regulatory NSP10 protein and a protein or peptide capable of being fused to NSP10 without interfering with the assembly or aggregation of the resulting fusion protein. The disclosure also relates to any nanoparticle formed thereby whether complete or not, and methods for the use of the NSP10 fusion protein are also disclosed, including use as vaccines for any indication in humans or animals, therapeutic methods involving the use of the fusion proteins such as using the protein to targeted an antibody or receptor, such as for treating or diagnosing cancer, biosensors using the fusion protein, or the use of the fusion proteins in cell sorting or any imaging application.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: January 31, 2023
    Inventor: Daniel C. Carter
  • Patent number: 11564983
    Abstract: The present invention relates to the production of the receptor binding domain (RBD) of the Spike glycoprotein 1 of the SARS-CoV-2 in mammalian cell expression systems, and the successive method of purification thereof. A recombinant plasmid containing the coding sequence of said RBD is produced and transfected in said mammalian cells, for example, Expi293. A high level of the protein is secreted in the medium and subsequently purified using the N-terminal tag, that can be removed by a specific protease. The present invention also includes a recombinant expression vector carrying the RBD gene, the successive methods for protein purification, the strategy for establishing a stable cell line producing the RBD, methods of use of the recombinant protein in formulating a pharmaceutical composition, including but not limited to, vaccines for preventing SARS-CoV-2 induced diseases.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: January 31, 2023
    Assignee: Betagen Scientific Limited
    Inventors: Alan Chang, Fabrizio Maria Anella, Clement M. Lee, Bing Lou Wong
  • Patent number: 11542527
    Abstract: The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (PIV5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: January 3, 2023
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventor: Biao He
  • Patent number: 11541113
    Abstract: The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: January 3, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John
  • Patent number: 11510977
    Abstract: Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: November 29, 2022
    Assignee: Suzhou Abogen Biosciences Co., Ltd.
    Inventor: Bo Ying
  • Patent number: 11512327
    Abstract: The invention provides compositions and methods for the preparation, manufacture, formulation and therapeutic use of adeno-associated virus (AAV) particles for the prevention and/or treatment of diseases.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: November 29, 2022
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Holger Patzke, Jinzhao Hou, Mathieu E. Nonnenmacher, Martin Goulet, Todd Carter
  • Patent number: 11510973
    Abstract: Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: November 29, 2022
    Assignee: GRITSTONE BIO, INC.
    Inventors: Wade Blair, Karin Jooss, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin
  • Patent number: 11504421
    Abstract: Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: November 22, 2022
    Assignee: GRITSTONE BIO, INC.
    Inventors: Wade Blair, Karin Jooss, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin
  • Patent number: 11484586
    Abstract: The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: November 1, 2022
    Assignees: Thomas Jefferson University, ICAHN School of Medicine at Mount Sinai
    Inventors: Matthias Schnell, Christine Rettew Fisher, Christoph Wirblich, Gene Tan
  • Patent number: 11434261
    Abstract: The present invention is directed to the expression and secretion the Zika virus envelope protein. Elements of the pre-membrane and envelope sequence have been modified to enhance the expression of the envelope protein as a secreted product in the culture medium of transformed insect cell lines. The expressed and purified product is suitable as a vaccine antigen.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: September 6, 2022
    Assignee: Hawaii Biotech Inc.
    Inventor: David E. Clements